Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Lazcluze (lazertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J, Oscotec, Yuhan Corp

Drug class:

EGFR inhibitor

Related drugs:

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1	lazertinib Sensitive: A1 - Approval lazertinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1	amivantamab-vmjw + lazertinib Sensitive: A1 - Approval amivantamab-vmjw + lazertinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials amivantamab-vmjw + lazertinib Sensitive : B	amivantamab-vmjw + lazertinib Sensitive: B - Late Trials amivantamab-vmjw + lazertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials lazertinib Sensitive : B	lazertinib Sensitive: B - Late Trials lazertinib Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	lazertinib Sensitive: B - Late Trials lazertinib Sensitive : B	lazertinib Sensitive: B - Late Trials lazertinib Sensitive : B
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2	lazertinib Sensitive: C2 – Inclusion Criteria lazertinib Sensitive : C2
EGFR L858R + MET positive	Non Small Cell Lung Cancer	EGFR L858R + MET positive	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3
EGFR exon 19 deletion + MET positive	Non Small Cell Lung Cancer	EGFR exon 19 deletion + MET positive	Non Small Cell Lung Cancer	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3	amivantamab-vmjw + lazertinib Sensitive: C3 – Early Trials amivantamab-vmjw + lazertinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D	lazertinib + ABN401 Sensitive: D – Preclinical lazertinib + ABN401 Sensitive : D